Harrow's Pollard steps down as chief accounting officer, Boll adds the role
Harrow, Inc. named CFO Andrew R. Boll as principal accounting officer after Randall E. Pollard's exit from that post, effective September 4, 2026.
SEC filing
Latest
8 stories
Tuesday, September 22
Wednesday, September 16
ImprimisRx NJ recalls ophthalmic solution for subpotency, Class III
Friday, September 4
Tuesday, September 1
Samsung Bioepis gets label supplement approved for Byooviz ranibizumab biosimilar
Friday, August 21
Completed trial compares Iheezo to standard anesthesia for intravitreal injections, lists Harrow as
Monday, August 10
Harrow reports Q2 2026 results, reiterates full-year guidance, cites pipeline progress
The ophthalmic disease company posted $70.7 million in quarterly revenue and pointed to several clinical and regulatory milestones expected through 2027.
SEC filing
Thursday, August 6
Harrow to acquire global rights to TYRVAYA nasal spray from Viatris
The $30 million upfront deal, with up to $70 million more tied to sales milestones, adds a second dry eye mechanism alongside Harrow's VEVYE franchise.
SEC filing
Viatris raises 2026 guidance, reports FDA approvals and Tyrvaya sale in Q2 update
Viatris lifted full-year guidance midpoints, won FDA approval for a new contraceptive patch, and agreed to sell Tyrvaya rights to Harrow as it navigates manufacturing disruptions in India.
SEC filing